3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
49
Phase 1
46
Phase 3
16
Phase 1/2
6
Phase EARLY_PHASE1
5
Phase 4
2
Phase NA
1
Status
Completed
2
Active not recruiting
2
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Breast
1
Conditions
Ovarian Neoplasms
1
Breast Neoplasms
1
BRCA or HRR+ Mutated Ovarian Cancer Patients
1
Interventions
Zoledronic Acid
28
Saline Solution
26
Metformin
25
Dexamethasone
25
Cyclophosphamide
23
Cytarabine
22
Bupivacaine
20
Sodium Chloride
18
Vincristine
17
Methotrexate
17
Letrozole
17
Propofol
15
Morphine
15
Doxorubicin
15
Prednisolone
14
Docetaxel
14
Dexmedetomidine
14
Cisplatin
14
Bevacizumab
14
Oxycodone
13
Imiquimod
13
Fentanyl
13
Capecitabine
13
Rituximab
12
Mercaptopurine
12
Fluorouracil
12
Granulocyte Colony-Stimulating Factor
11
Everolimus
11
Asparaginase
11
Acetaminophen
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Completed
×
olaparib
×
Clear all
NCT04330040
2025-03-10
SOLI
AstraZeneca
Phase 4
Completed
202 enrolled
15 charts
NCT02476968
2022-09-10
ORZORA
AstraZeneca
Phase 4
Completed
181 enrolled
24 charts